"Pharmaceutical Speed Reader" 4 plus 7 expansion varieties again appear shortage Takeda Walker layout China market

186 drugs transferred out of Guangxi medical insurance; new three-plate transfer to the main board 6 pharmaceutical companies sprint first; Lilly insulin glargine treatment of China's adult type 2 diabetes phase III clinical reach the main end point; treatment RA Gilead released two Phase 3 clinical 52 weeks data; Takeda Walker layout of the Chinese market ..The State Administration of Health Insurance issued on the 4th "on the publicity of medical insurance medical supplies classification and code database of the second batch of medical supplies information notice", the content of the "National Medical Security Administration on the issuance of medical security standardization work guidance notice" related requirements, the second batch of medical supplies information will now be made public(National Medical Insurance Bureau)Guangxi Zhuang Autonomous Region Medical Insurance Bureau issued on the 4th on the adjustment of the norms of the Guangxi Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalog noticeThe adjusted Guangxi "Drug Catalog" includes 1645 Western medicines, 1759 Chinese traditional medicines (including 97 ethnic drugs), and 118 drugs negotiated during the agreement period (including 95 Western medicines and 23 Chinese medicines), for a total of 3522(Guangxi Zhuang Autonomous Region Medical Insurance Bureau)Yunnan Provincial Medical Insurance Bureau on the 4th issued the "Yunnan Provincial Medical Security Bureau on the submission of written information statements and capacity list of letters." The documents show a shortage of eight varieties of the 4 plus 7 expansion, namely, enticave dispersal tablets, attovastatin calcium tablets, lipasterone tablets, Malayacid inapis tablets, benzodiazepines, ebeceatan tablets, cephalosporine tablets, and monites(Yunnan Provincial Health Insurance Bureau)china securities regulatory commission issued guidance, the pilot allows qualified new three-plate listed companies, apply for the transfer board to the Shanghai Stock Exchange Or Shenzhen Stock Exchange GEM listingThe enterprise applying for listing of the transfer board shall list the company at the new three-plate select layer, and if the list editing at the select layer is continuous for more than one year, it shall also meet the listing conditions for the transfer plateAmong the accepted enterprises, pharmaceutical enterprises have become quite worthy of attentionOf the 47 accepted enterprises, 6 are in the pharmaceutical sector(E drug manager)announced on the 5th that Basaglar ® (insulin glargine) in China adult type 1 diabetes patients in the phase III clinical study reached the main research end point, Lilly on the 5th again announced that a more long-acting basic insulin analogue in China's adult type 2 diabetes patients Baslarag ® (insulingling) and the effectiveness and safety of the time ® (insulingl) for a period of 24 weeks of clinical phase III studies reached the main end point(Sina Pharmaceutical News)Novartis announced positive results from a 52-week phase 3 clinical trial, which showed substantial and lasting benefits for patients with mid-axis spinal arthritis (axSpA) in The Secukinumab, commonly known as "Sukin monotophosis." (Sina Pharmaceutical News)AbbVie recently announced the new long-term results of oral JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis: from two Stage III clinical SELECT-COMPARE (Rinvoq 15mg combined metformin) Data from dedees (MTX) and SELECT-MONOTHERAPY (Rinvoq 15mg and 30mg) show that oral Rinvoq treatment is continued to improve symptoms and signs in RA patients at 72 and 84 weeks of oral Rinvoq treatment once a day (Sina Pharmaceutical News) , Gilead Sciences and Galapagos inc announced the 52nd week of data from filgotinib's treatment of moderate-moderate active rheumatoid arthritis (RA) in two phase III clinical trials, FINCH 1 and FINCH 3 The results showed that after 52 weeks of treatment, filgotinib showed long-lasting efficacy and consistent safety in RA patients (SINA Pharmaceutical News) Pfizer announced that the full results of the second critical phase 3 clinical trial developed by the company to treat aspecific dermatitis were released on JAMA Dermatology Abrocitinib is a research oral JAK1 inhibitor (once a day) used in patients aged 12 and over with moderate to severe adhesitis Consistent with the first phase 3 single drug therapy study, both doses of abrocitinib reached all common primary and critical secondary endpoints and were well tolerated (Pharmaceutical Mingkang) CDE official website shows that Takeda Pharmaceuticals domestic submitted its Walker (Fuma acid Vonolason tablets) new indication application, involving two acceptance numbers, has been CDE acceptance contractor It is worth noting that this is the second new indication application for the market listing of Takeda Fuma acid Vonola tablets less than half a year after China was approved, and the speed of the chinese market layout is rare among foreign pharmaceutical companies (CPhI PharmaceuticalSOnline) Johnson and Johnson's Janssen Pharmaceuticals recently announced new data for two Phase III clinical studies at the European Union electronic conference on rheumatism in 2020 The two studies assessed the efficacy and safety of Tremfya (Tenoya®, generic name: guselkumab, gusecusm) in adult patients with active psoriasis arthritis New data show that during the 52nd week of treatment, Tremfya showed improvements in a number of clinical outcomes, including joint symptoms, skin symptoms, soft tissue inflammation, body function, and reduced imaging progress (Biological Valley) Zhengda Tianqing submitted four types of generic drug Entquata Binti nofuwei tablet listing application obtained the approval of the State Drug Administration, become the first imitation in China, and as the same through the consistency evaluation; This is the third domestic manufacturer to submit a generic drug listing application after Haizheng Pharmaceuticals and Haussen Pharmaceuticals (Pharma Rubik's Cube) Hausson Pharmaceuticals submitted four generic drug Malay acid Afatini tablets listed application obtained by the State Drug Administration approval, become the first imitation in China; This is the first insulin product approved for listing by Dongsun, and the application for listing of Liss's Clear-Through Dermal Patch submitted by Green Leaf Pharmaceuticals under category 5.2 (overseas generic applications for domestic listing) was approved by the State Drug Administration (Pharma Rubik's Cube) Haizheng Pharmaceuticals 2 new 4 types of generic drugs (Fumaacid isosulphate flat release tablets and hydrochloric acid donated tablets) approved by the State Drug Administration for listing and as if passed the consistency evaluation Among them, Fumaatic sulphate flat release tablet slowly for the second domestic through consistency evaluation, hydrochloric acid Donnai Qikou collapse tablets for the first in China Both products were approved by the FDA in 2018 (Pharmaceutical Rubik's Cube) the U.S FDA announced the approval of The Innovative Antibiotic Recarbrio Extended Indications developed by Mercado to treat patients with acquired bacterial pneumonia and ventilator-related bacterial pneumonia in hospitals over the age of 18 Recarbrio was previously fda-approved for the treatment of complex urinary tract infections and complex intracavity infections (Pharmaceutical Mingkang) Y-mAbs recently announced that the U.S FDA has accepted Danyelza's biological products for the treatment of recurrent/refractive high-risk neuroblastoma and granted priority review, while the target action date has been designated as November 30, 2020 The agency also indicated in the BLA acceptance letter that it did not intend to convene an advisory committee to discuss the application at this time (Biovalley) Japanese pharmaceutical company Yukio Yano recently announced that the U.S FDA has accepted the new antibacterial drug Fetroja (cefiderocol, cephalosporine) supplementapplication new drug application and granted priority review, and has designated the prescription drug user fee law target date of September 27, 2020 The sNDA seeks approval for fetroja for a new indication that is used in hospital-acquired bacterial pneumonia and ventilator-related bacterial pneumonia in adult patients (BioValley) recently published the results of a phase I clinical study of CAR-T cell therapy for advanced hepatocellular carcinoma, the first globally published clinical results of CAR-T cell therapy targeting GPC3 solid tumors, demonstrating the clinical application potential of CAR-T therapy in liver cell carcinoma (CPhI Pharmaceuticals Online)